BR112022009100A2 - Peptídeos antigênicos para prevenção e tratamento de malignidade de células b - Google Patents
Peptídeos antigênicos para prevenção e tratamento de malignidade de células bInfo
- Publication number
- BR112022009100A2 BR112022009100A2 BR112022009100A BR112022009100A BR112022009100A2 BR 112022009100 A2 BR112022009100 A2 BR 112022009100A2 BR 112022009100 A BR112022009100 A BR 112022009100A BR 112022009100 A BR112022009100 A BR 112022009100A BR 112022009100 A2 BR112022009100 A2 BR 112022009100A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigenic peptides
- malignity
- prevention
- cell
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306475 | 2019-11-15 | ||
| EP2020079257 | 2020-10-16 | ||
| PCT/EP2020/082101 WO2021094562A2 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009100A2 true BR112022009100A2 (pt) | 2022-07-26 |
Family
ID=75911928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009100A BR112022009100A2 (pt) | 2019-11-15 | 2020-11-13 | Peptídeos antigênicos para prevenção e tratamento de malignidade de células b |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11759508B2 (https=) |
| EP (2) | EP4357356A3 (https=) |
| JP (1) | JP2023501204A (https=) |
| CN (1) | CN114746112A (https=) |
| AU (1) | AU2020384926B2 (https=) |
| BR (1) | BR112022009100A2 (https=) |
| CA (2) | CA3290212A1 (https=) |
| DK (1) | DK4021487T5 (https=) |
| ES (1) | ES2971929T3 (https=) |
| FI (1) | FI4021487T3 (https=) |
| HR (1) | HRP20240116T1 (https=) |
| HU (1) | HUE065075T2 (https=) |
| LT (1) | LT4021487T (https=) |
| MX (1) | MX2022005704A (https=) |
| PL (1) | PL4021487T3 (https=) |
| RS (1) | RS65262B1 (https=) |
| SI (1) | SI4021487T1 (https=) |
| SM (1) | SMT202400048T1 (https=) |
| WO (1) | WO2021094562A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622188B1 (ko) | 2016-10-07 | 2024-01-05 | 엔터롬 에스.에이. | 암 치료를 위한 면역원성 화합물 |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| CN112118863B (zh) | 2018-04-11 | 2025-05-30 | 恩特罗姆公司 | 用于预防和治疗癌症的抗原肽 |
| JP2025081784A (ja) * | 2022-03-01 | 2025-05-28 | ｂｉｔＢｉｏｍｅ株式会社 | アミノ酸残基配列を同定するための方法，プログラム及び記録媒体 |
| JP2025526447A (ja) * | 2022-07-29 | 2025-08-13 | エルジー・ケム・リミテッド | 抗原送達用組換え融合タンパク質およびその使用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| ES2275499T3 (es) | 1999-03-19 | 2007-06-16 | Glaxosmithkline Biologicals S.A. | Vacuna contra streptococcus pneumoniae. |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| WO2005007673A2 (en) * | 2003-07-03 | 2005-01-27 | Rush University Medical Center | Immunogenic peptides |
| SI2119726T2 (en) | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| EP2797634A4 (en) | 2011-12-29 | 2015-08-05 | Moderna Therapeutics Inc | MODIFIED MRNAS FOR THE CODING OF CELL-PENETRATING POLYPEPTIDES |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| EP3446119A1 (en) * | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| CN106008695A (zh) * | 2016-06-19 | 2016-10-12 | 苏州普罗达生物科技有限公司 | 一种关于cd19免疫原多肽及其用途 |
| KR102622188B1 (ko) * | 2016-10-07 | 2024-01-05 | 엔터롬 에스.에이. | 암 치료를 위한 면역원성 화합물 |
| WO2019051001A1 (en) * | 2017-09-06 | 2019-03-14 | California Institute Of Technology | SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR) |
| WO2019072871A2 (en) * | 2017-10-09 | 2019-04-18 | Enterome S.A. | MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR |
| CN112118863B (zh) * | 2018-04-11 | 2025-05-30 | 恩特罗姆公司 | 用于预防和治疗癌症的抗原肽 |
| WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
-
2020
- 2020-11-13 ES ES20804279T patent/ES2971929T3/es active Active
- 2020-11-13 EP EP23220228.3A patent/EP4357356A3/en active Pending
- 2020-11-13 SI SI202030352T patent/SI4021487T1/sl unknown
- 2020-11-13 SM SM20240048T patent/SMT202400048T1/it unknown
- 2020-11-13 RS RS20240132A patent/RS65262B1/sr unknown
- 2020-11-13 HU HUE20804279A patent/HUE065075T2/hu unknown
- 2020-11-13 PL PL20804279.6T patent/PL4021487T3/pl unknown
- 2020-11-13 CA CA3290212A patent/CA3290212A1/en active Pending
- 2020-11-13 JP JP2022525171A patent/JP2023501204A/ja active Pending
- 2020-11-13 LT LTEPPCT/EP2020/082101T patent/LT4021487T/lt unknown
- 2020-11-13 CN CN202080083161.5A patent/CN114746112A/zh active Pending
- 2020-11-13 WO PCT/EP2020/082101 patent/WO2021094562A2/en not_active Ceased
- 2020-11-13 EP EP20804279.6A patent/EP4021487B1/en active Active
- 2020-11-13 DK DK20804279.6T patent/DK4021487T5/da active
- 2020-11-13 HR HRP20240116TT patent/HRP20240116T1/hr unknown
- 2020-11-13 MX MX2022005704A patent/MX2022005704A/es unknown
- 2020-11-13 FI FIEP20804279.6T patent/FI4021487T3/fi active
- 2020-11-13 AU AU2020384926A patent/AU2020384926B2/en active Active
- 2020-11-13 CA CA3153470A patent/CA3153470A1/en active Pending
- 2020-11-13 BR BR112022009100A patent/BR112022009100A2/pt unknown
-
2022
- 2022-05-02 US US17/734,694 patent/US11759508B2/en active Active
-
2023
- 2023-07-19 US US18/354,966 patent/US20240033335A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021094562A3 (en) | 2021-09-30 |
| ES2971929T3 (es) | 2024-06-10 |
| LT4021487T (lt) | 2024-02-12 |
| DK4021487T3 (da) | 2024-02-12 |
| EP4021487A2 (en) | 2022-07-06 |
| JP2023501204A (ja) | 2023-01-18 |
| AU2020384926A1 (en) | 2022-04-28 |
| WO2021094562A2 (en) | 2021-05-20 |
| DK4021487T5 (da) | 2024-07-29 |
| US20240033335A1 (en) | 2024-02-01 |
| US11759508B2 (en) | 2023-09-19 |
| PL4021487T3 (pl) | 2024-04-15 |
| RS65262B1 (sr) | 2024-03-29 |
| AU2020384926B2 (en) | 2025-09-18 |
| EP4357356A3 (en) | 2024-07-31 |
| CA3153470A1 (en) | 2021-05-20 |
| HUE065075T2 (hu) | 2024-04-28 |
| MX2022005704A (es) | 2022-06-08 |
| CN114746112A (zh) | 2022-07-12 |
| EP4357356A2 (en) | 2024-04-24 |
| CA3290212A1 (en) | 2026-03-02 |
| SI4021487T1 (sl) | 2024-03-29 |
| US20220323561A1 (en) | 2022-10-13 |
| SMT202400048T1 (it) | 2024-03-13 |
| FI4021487T3 (fi) | 2024-02-06 |
| HRP20240116T1 (hr) | 2024-04-12 |
| EP4021487B1 (en) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009100A2 (pt) | Peptídeos antigênicos para prevenção e tratamento de malignidade de células b | |
| MX2023014457A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer. | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| PH12021552476A1 (en) | Compositions and methods for preparing t cell compositions and uses thereof | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
| BR112018073221A2 (pt) | métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina | |
| UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
| MX2013001613A (es) | Métodos y composiciones para prevenir una afección. | |
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| WO2018065623A3 (en) | Immunogenic compounds for cancer therapy | |
| BR112022003740A2 (pt) | Anticorpos anti-cd96 e métodos de uso dos mesmos | |
| WO2018065625A3 (en) | Immunogenic compounds for cancer therapy | |
| MX380003B (es) | Péptidos topk y vacunas que incluyen los mismos. | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| BR112014001363A2 (pt) | peptídeos mphosph1 e vacinas incluindo os mesmos | |
| MX2024011785A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo | |
| BR112013009526A2 (pt) | peptídeos de wdhd1 e vacinas incluindo os mesmos |